7326-79-6

Basic information

• Product Name: 3-(pyrrolidin-1-ylsulfonyl)benzoic acid
• Synonyms: 3-(1-pyrrolidinylsulfonyl)benzoic acid;3-(pyrrolidin-1-ylsulfonyl)benzoic acid
• CAS NO: 7326-79-6
• Molecular Formula: C11H13NO4S
• Molecular Weight: 255
• EINECS: -0
• Mol File: 7326-79-6.mol
• Article Data: 3

Chemical Properties

• Melting Point: 149～151℃
• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3-(pyrrolidin-1-ylsulfonyl)benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(pyrrolidin-1-ylsulfonyl)benzoic acid(7326-79-6)
• EPA Substance Registry System: 3-(pyrrolidin-1-ylsulfonyl)benzoic acid(7326-79-6)

Safety Data

• Hazardous Substances Data: 7326-79-6(Hazardous Substances Data)

Usage

General Description

3-(pyrrolidin-1-ylsulfonyl)benzoic acid is a chemical compound with the molecular formula C14H17NO4S. It is a sulfonamide derivative of benzoic acid and contains a pyrrolidinyl group. 3-(pyrrolidin-1-ylsulfonyl)benzoic acid is often used as an intermediate in the synthesis of pharmaceutical drugs, agrochemicals, and other organic compounds. It has potential applications in the fields of medicinal chemistry and chemical research due to its unique structure and properties. The presence of the sulfonamide and benzoic acid groups in the molecule makes it a versatile building block for the creation of new and more effective compounds. Additionally, its pyrrolidinyl group adds to its potential pharmacological and biological activities, making it an important and valuable chemical compound in the field of organic chemistry.

Upstream product

• 123-75-1 pyrrolidine 
• 4025-64-3 3-Carboxybenzenesulfonyl chloride 
• 65-85-0 benzoic acid 

Downstream Products

• 1227685-46-2 3-(pyrrolidine-1-sulfonyl)-benzaldehyde 

Relevant articles and documents

Synthesis and Biological Evaluation of 4-Sulfamoylphenyl/Sulfocoumarin Carboxamides as Selective Inhibitors of Carbonic Anhydrase Isoforms hCA II, IX, and XII

With the aim to develop potent and selective human carbonic anhydrase inhibitors (hCAIs), we synthesized 4-sulfamoylphenyl/sulfocoumarin benzamides (series 5 a–r and series 7 a–q) and evaluated their inhibition profiles against five isoforms of the zinc-containing human carbonic anhydrase (hCA, EC 4.2.1.1): cytosolic hCA I and II, and the transmembrane isozymes hCA IV, IX, and XII. Compounds 5 a–r were found to selectively inhibit hCA II in the nanomolar range, while being less effective against the other hCA isoforms. As noted from the literature, sulfocoumarin (1,2-benzoxathiine 2,2-dioxide) acts as a “prodrug” inhibitor and is hydrolyzed by the esterase activity of hCA to form 2-hydroxyphenylvinylsulfonic acid, which thereafter binds to the enzyme in a manner similar to that of coumarins and sulfoxocoumarins. All these sulfocoumarins (compounds 7 a–q) were found to be very weak or ineffective as inhibitors of the housekeeping off-target hCA isoforms I and II, and effectively inhibited the transmembrane tumor-associated isoforms IX and XII in the high nanomolar to micromolar ranges. Further structural modifications of these molecules could be useful for the development of effective hCA inhibitors used for the treatment of glaucoma, epilepsy, and cancer.

COMPOUNDS HAVING CRTH2 ANTAGONIST ACTIVITY

Compounds of general formula (I): wherein W is chloro or fluoro; Z is a group SO2R1; wherein R1 is -C3-C8 cycloalkyl or heterocyclyl optionally substituted with one or more substituents chosen from halo, -CN, -C1-C6 alkyl, -SOR3, -SO2R3, -SO2N(R2)2, -N(R2)2, -NR2C(O)R3, -CO2R2, -CONR2R3, -NO2, -OR2, -SR2, -O(CH2)POR2, and - O(CH2)pO(CH2)qOR2 wherein each R2 is independently hydrogen, -Ci-C6 alkyl, -C3-C8 cycloalkyl, aryl or heteroaryl; each R3 is independently, -C1-C6 alkyl, -C3-C8 cycloalkyl, aryl or heteroaryl; p and q are each independently an integer from 1 to 3; and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.